LIVEKIDNEY.BIO
Regenerative Medicine Therapies for Kidney Disease
Company Overview
Snapshot
Founded in November 2009, LIVEKIDNEY.BIO operates with 1–10 employees. The company has raised $4 million across one funding round from two investors. In November 2018, the company secured seed funding from Aurum Ventures M.K.I and Jonathan Leitersdorf.
Business overview
LIVEKIDNEY.BIO is a biotechnology company focused on developing regenerative medicine therapies for kidney disease. The company utilizes a proprietary cell-derived delivery platform, which combines sustained-release hydrogel formulations with AI-enabled data analytics. Its core technology is an AI-based cell-derived therapy designed to improve kidney function in patients with chronic kidney disease and enhance the general medical condition of those with Lupus. LIVEKIDNEY.BIO operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development markets with its cell therapy-based products.
Strategic signal
In February 2019, LIVEKIDNEY.BIO was highlighted for its potential to delay dialysis for patients suffering from chronic kidney disease. This signals the company's progress in developing innovative treatments that could significantly impact patient care and reduce the economic burden associated with advanced kidney disease, validating its approach to regenerative medicine.
Log in to access full profile ›Company Intelligence Q&A
- What is LIVEKIDNEY.BIO's primary focus?
- LIVEKIDNEY.BIO is focused on developing regenerative medicine therapies for kidney disease, utilizing a proprietary cell-derived delivery platform.
- When was LIVEKIDNEY.BIO founded?
- LIVEKIDNEY.BIO was founded in November 2009.
- What is the core technology behind LIVEKIDNEY.BIO's therapies?
- The company's core technology involves sustained-release hydrogel formulations combined with AI-enabled data analytics to create AI-based cell-derived therapies.
- How much funding has LIVEKIDNEY.BIO raised?
- In November 2018, LIVEKIDNEY.BIO raised $4 million in seed funding from Aurum Ventures M.K.I and Jonathan Leitersdorf.
- Which investors participated in LIVEKIDNEY.BIO's seed funding round?
- In November 2018, LIVEKIDNEY.BIO secured seed funding from Aurum Ventures M.K.I and Jonathan Leitersdorf.